ADMA Biologics Inc (NASDAQ:ADMA) Shares Purchased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. grew its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 43.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 55,287 shares of the biotechnology company's stock after acquiring an additional 16,871 shares during the period. Oppenheimer & Co. Inc.'s holdings in ADMA Biologics were worth $1,097,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ADMA. Mark Sheptoff Financial Planning LLC bought a new stake in ADMA Biologics during the fourth quarter valued at approximately $35,000. Farther Finance Advisors LLC grew its position in shares of ADMA Biologics by 1,149.1% during the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 2,505 shares in the last quarter. Vision Financial Markets LLC purchased a new stake in shares of ADMA Biologics during the 4th quarter worth approximately $51,000. AlphaQuest LLC purchased a new position in shares of ADMA Biologics in the 4th quarter worth $84,000. Finally, GF Fund Management CO. LTD. bought a new stake in ADMA Biologics during the fourth quarter worth approximately $85,000. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Price Performance

NASDAQ ADMA traded up $0.14 during mid-day trading on Wednesday, hitting $18.02. The stock had a trading volume of 1,065,365 shares, compared to its average volume of 3,690,904. The stock has a market capitalization of $4.30 billion, a price-to-earnings ratio of 21.11 and a beta of 0.43. ADMA Biologics Inc has a twelve month low of $10.21 and a twelve month high of $25.67. The firm's 50 day moving average is $20.47 and its 200 day moving average is $18.74. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The firm had revenue of $114.80 million for the quarter, compared to analysts' expectations of $116.40 million. During the same period in the previous year, the firm posted $0.08 EPS. The firm's quarterly revenue was up 40.2% compared to the same quarter last year. Equities research analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ADMA shares. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th. Raymond James Financial boosted their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th.

Insider Activity

In other news, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the transaction, the director owned 478,194 shares in the company, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Lawrence P. Guiheen sold 20,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the sale, the director owned 94,830 shares of the company's stock, valued at $1,987,636.80. This represents a 17.42% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 464,621 shares of company stock worth $9,644,269. 3.70% of the stock is currently owned by company insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.